Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TherapeuticsMD, Inc. TXMD
$4.45
+$0.5 (11.25%)
На 18:00, 12 мая 2023
+12.36%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
43903962.00000000
-
week52high
11.69
-
week52low
1.99
-
Revenue
69963000
-
P/E TTM
-2
-
Beta
1.17439400
-
EPS
0.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Neutral | 13 июл 2022 г. | |
| HC Wainwright & Co. | Neutral | Buy | 07 июн 2022 г. |
| Cantor Fitzgerald | Neutral | Overweight | 06 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Donegan Michael C | D | 11853 | 49 | 27 янв 2023 г. |
| Donegan Michael C | D | 0 | 1140 | 26 янв 2023 г. |
| Donegan Michael C | D | 11902 | 1648 | 26 янв 2023 г. |
| Donegan Michael C | A | 13550 | 1140 | 26 янв 2023 г. |
| Donegan Michael C | A | 12410 | 2400 | 26 янв 2023 г. |
| Donegan Michael C | A | 10010 | 2400 | 26 янв 2023 г. |
| Donegan Michael C | D | 7610 | 7 | 24 янв 2023 г. |
| Donegan Michael C | D | 0 | 2400 | 23 янв 2023 г. |
| Donegan Michael C | D | 7617 | 1302 | 23 янв 2023 г. |
| Donegan Michael C | A | 8919 | 2400 | 23 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 3445600 | 3445600 | 31 мар 2022 г. |
| Vanguard Total Stock Market Index Fund | 6637800 | -94637 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 4989910 | 142880 | 31 авг 2020 г. |
| iShares NASDAQ Biotechnology ETF | 2784900 | -55638 | 31 авг 2020 г. |
| Fidelity Series Large Cap Stock Fund | 8186710 | 0 | 31 июл 2020 г. |
| JPMorgan Small Cap Growth Fund | 5917540 | 219996 | 31 июл 2020 г. |
| Baron Discovery Fund | 3831500 | 0 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 3294780 | -77025 | 31 июл 2020 г. |
| T. Rowe Price Small Cap Stock Fund | 9153310 | -35300 | 30 июн 2020 г. |
| T. Rowe Price Institutional Small-Cap Stock Fund | 4846800 | -319528 | 30 июн 2020 г. |
Новостная лента
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
Zacks Investment Research
14 апр 2023 г. в 13:42
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 21:03
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
15 авг 2022 г. в 09:47
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
15 авг 2022 г. в 09:46
TherapeuticsMD, Inc. (NASDAQ:TXMD ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator [Starts Abruptly] for the Therapeutics MD's Second Quarter 2022 Financial Results Conference Call.
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
Business Wire
08 авг 2022 г. в 06:50
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Monday, August 15, 2022 Time: 8:30 a.m. ET